Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4385MR)

This product GTTS-WQ4385MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Kidney transplant rejection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4385MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9785MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ7952MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ14541MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ8378MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ6647MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ14699MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ5058MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ15703MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW